Triple-negative breast cancer (TNBC) makes up about 10% to 15% of breast cancer diagnoses and tends to be more aggressive than other breast cancers.
Dr. Foluso Ademuyiwa answers questions about symptoms, side-effects, and treatment options for early-stage and metastatic TNBC.
On this page
About our speaker
Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI
Foluso Olabisi Ademuyiwa (Bisi), MD, MPH, MSCI, is a breast medical oncologist and associate professor at Washington University in St. Louis. She is an expert in the management of all types of breast cancer. She provides patient-centered care as part of a multidisciplinary breast cancer team. Dr. Ademuyiwa is actively involved in research on triple-negative breast cancer and racial disparities in breast cancer research and serves as principal investigator on multiple clinical trials.
Learn moreThank you to our sponsors
Signature
Benefactor
Stay connected
Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.